Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The STEPs educational framework for medicines management: using mnemonics to reduce harm.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Proteasome inhibition enhances lysosome-mediated targeted protein degradation.

Cell death & disease·2026
Same author

American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.

Blood advances·2026
Same author

Hypochlorous Acid-Gated Hydrolysis of a Phosphinate Ester Dye in Living Cells.

Journal of the American Chemical Society·2025
Same author

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

British journal of haematology·2025
Same author

A Heart of Myeloid: Extramedullary Chronic Myelomonocytic Leukemia-2 Presenting as a Myeloid Sarcoma of the Pericardium Causing Recurrent Pericardial Effusions.

Journal of medical cases·2025

Related Experiment Video

Updated: Mar 24, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Update on rational targeted therapy in AML.

Danielle Shafer1, Steven Grant1

  • 1Virginia Commonwealth University, Richmond, VA, USA.

Blood Reviews
|March 15, 2016
PubMed
Summary
This summary is machine-generated.

New treatments for acute myeloid leukemia (AML) show promise, including epigenetic modifiers and signaling inhibitors. Combining these novel agents may offer better long-term disease control for AML patients.

Keywords:
Aurora kinaseBETBH3-mimeticDOT1LFlavopiridolHDAC inhibitorsHedgehogHigh-risk AMLIDHIdasanutlinLSD1PalbociclibPevonedistatRigosertibTosedostatVenetoclaxVolasertibWee1

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

903

Related Experiment Videos

Last Updated: Mar 24, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

903

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) presents significant challenges with limited treatment advancements and poor patient outcomes.
  • Despite increased understanding of AML pathogenesis, therapeutic options remain restricted.

Purpose of the Study:

  • To review novel therapeutic targets and agents currently in development for acute myeloid leukemia.
  • To explore the potential of combining novel agents for improved long-term AML management.

Main Methods:

  • Literature review of recent advancements in AML drug development.
  • Analysis of targeted therapies including epigenetic modifiers and cell cycle inhibitors.

Main Results:

  • Identified several classes of novel agents for AML, including IDH inhibitors, BET inhibitors, HDAC inhibitors, Aurora kinase inhibitors, and CDK inhibitors.
  • Highlighted the potential of rational combination therapies for enhanced efficacy.

Conclusions:

  • Novel targeted therapies offer encouraging prospects for acute myeloid leukemia treatment.
  • Single-agent therapy is unlikely to achieve durable disease control; combination strategies are crucial for future AML treatment paradigms.